One Month Earlier, Eight Years Later: What China’s 2026 Formulary Consultation Means for Ophthalmology
NHSA advances the 2026 formulary cycle by one month and links commercial insurance to basic formulary eligibility. The anti-VEGF 8-year pricing crossroads is now.
China’s 2026 national drug formulary consultation opened on 9 May. It advances the annual cycle by approximately one month, introduces pre-submission rights for drugs with completed technical review, and formally links commercial insurance coverage to basic formulary eligibility. None of this is the most consequential signal in the document for ophthalmology. The sharper question is what happens when anti-VEGF drugs that entered the formulary in 2017 now sit at the 8-year threshold where pricing can lock in permanently, and whether the revolving door between commercial and basic insurance that NHSA has just formalised on paper can actually turn in practice.
What Pre-Submission Actually Does
The mechanism is straightforward in design. Drugs that have completed technical review at NMPA but have not yet received formal approval may now file formulary applications before their registration certificate is issued. Under previous rules, the cut-off was formal approval before 30 June. The 2026 draft shifts the cut-off to the date the formal plan is published, expected by the end of May. [NHSA consultation document, 9 May 2026]
NHSA states the overall cycle will start approximately one month earlier than in prior years. Industry analyst Guo Xinfeng (CEO, Nanjing Evidence Biosciences) frames the individual drug-level impact more precisely: by removing the forced wait for formal approval, the pre-submission mechanism could compress the approval-to-formulary timeline for an individual drug by an estimated three to six months. [Third-party expert estimate, attributed]
A policy-execution gap is already visible. “Completion of technical review” is the eligibility threshold, but companies must self-certify their NMPA review status, and the preparation window between the consultation closing (15 May, 17:00 Beijing time) and the formal submission window (June–July) is compressed to days, not weeks. For companies near the eligibility boundary, this is an immediate operational question.
The Commercial Insurance Dual-Track: Design and Execution
The 2026 consultation adds three new application pathways for drugs not yet in the basic formulary. The most significant: drugs already listed on China’s commercial health insurance innovative drug list may now formally apply for basic formulary inclusion. The reverse pathway, commercial insurance list drugs applying again when new indications are approved, is also formalised. [NHSA consultation document, 9 May 2026]
The institutional logic is deliberate. Products priced above the “protect the basics” threshold of basic insurance enter commercial insurance coverage first; clinical utilisation evidence accumulates; the product migrates to basic formulary later at adjusted pricing. The 2026 draft has codified this architecture in both directions.
The first commercial health insurance innovative drug list launched in 2025, covering 19 drugs, CAR-T therapies, rare disease treatments, and oncology targeted agents. No ophthalmology drugs were included. [NHSA official Q&A, 9 May 2026]
The execution record from that first version is unambiguous. Implementation was impeded by a structural constraint: drug company discounts cannot appear on hospital invoices; insurers can only reimburse at invoice price; compliant discount-return mechanisms via third-party administrators remain legally unsettled. Hospital procurement committees have not moved quickly. Physician prescription incentives within hospital performance management systems have not been adjusted. [NHSA official Q&A; industry participant assessments reported in specialist press]
This is a policy-execution gap operating at the mechanism level, not the regulatory intent level. The revolving door exists in the legal text. The practical flow through it is blocked by infrastructure constraints that formal rules alone cannot resolve.
One additional mechanism formalised in the 2026 consultation: competitive drugs entering the formulary will face a price warning system. Hospital procurement prices exceeding 1.8 times the payment standard receive a yellow label; those exceeding three times receive a red label. [NHSA official Q&A, 9 May 2026] Previously applied in provincial device procurement, this price-signalling logic is now national in scope for formulary drugs, a precedent signal for high-value consumables pricing governance.
Three Ophthalmology Signals
Signal One — The Anti-VEGF 8-Year Crossroads
Ranibizumab (Lucentis, Novartis) entered China’s national drug formulary through the 2017 national negotiation round, with formal inclusion under the Ministry of Human Resources and Social Security document No.54 (人社部发 [2017] 54号). [Independently confirmed: NHSA No.147 (医保函 [2019] 147号), 24 September 2019] It has now reached the 8-year threshold stipulated in the 2026 draft renewal rules.
Under the draft rules, drugs at the 8-year milestone face a pricing crossroads. Transferring to common catalogue management locks the current reimbursement price permanently and removes the drug from future annual negotiation cycles. Continuation under simple renewal terms maintains annual markdown exposure but retains pricing optionality, including the possibility of re-entering negotiation if a new indication is approved. The 2026 draft reduces the required markdown for drugs in their fifth or subsequent consecutive agreement year, softening but not eliminating the renewal pathway.
Conbercept (Lumitin, Kanghong Pharmaceutical) transferred to common catalogue management at the end of 2025, the first anti-VEGF drug in China to do so. Its reimbursement price is now fixed. Kanghong’s high-dose variant is currently in Phase III clinical trials; formal approval would create a new application pathway via new indication submission.
Two structural constraints remain constant regardless of which pathway is chosen. First, formulary payment conditions for anti-VEGF drugs include lifetime injection limits per eye, a volume ceiling that restricts long-term franchise growth independently of formulary status. Second, the 2026 draft shows no movement on that ceiling. The 8-year decision for ranibizumab is not a forward-looking planning item. It is a current-cycle question.
Signal Two — Commercial Insurance and High-End IOL
OphthalLogix Analytical Judgement. The following is based on publicly available information and does not represent a statement of current regulatory policy or confirmed direction.
The formalisation of the commercial insurance dual-track creates, in principle, an institutional pathway for premium medical devices, including high-end intraocular lenses. The structural fit is logical: premium IOLs exceed the “protect the basics” threshold of basic insurance; they represent precisely the category of high-value innovation that the commercial insurance pathway was designed to accommodate.
The execution barrier is the same one documented on the drug side, and it applies with equal or greater force to devices. Hospital procurement dynamics, invoice-discount mismatches, and physician incentive structures have impeded the drug-side pathway despite sustained policy backing. The device side begins this journey without the preparation time the drug side has had.
The revolving door for high-end IOL is institutionally open. It is not currently turning. The medium-term question for IOL market access teams is whether the drug-side execution constraints will resolve in 2026, because their resolution creates the infrastructure conditions that would make device-side access viable. If they do not resolve, commercial insurance for premium IOL remains a logical possibility with unresolved operational barriers.
Signal Three — The Access Gateway Principle
OphthalLogix Analytical Judgement.
China’s medical insurance system covers approximately 1.4 billion enrolled individuals. Formulary inclusion is not one access pathway among several; it is the primary channel through which a product reaches the majority of China’s hospital market at volume. Companies that work the formulary-procurement dual track systematically, formulary positioning, procurement selection, quality and price differentiation, clinical evidence accumulation, hold a structural market access advantage that private-pay and commercial insurance channels cannot replicate at scale.
For IOL companies specifically, this formulary consultation does not alter the operative 2026 strategy framework. Formulary position, procurement selection plus product differentiation remains the primary architecture. The commercial insurance channel is a watch item, not a redeployment target. What this consultation does change: the window to make the anti-VEGF 8-year crossroads decision is this cycle.
Key Implications
For ophthalmology companies managing anti-VEGF portfolios. The 8-year threshold under the 2026 draft renewal rules is not a future scenario. Ranibizumab is at the threshold. The choice between common catalogue management (permanent price lock, no annual renegotiation) and simple renewal (markdown exposure, retained optionality on future indications) requires a position before the formal submission window opens in June.
For market access teams tracking commercial insurance as a device access pathway. The revolving door exists in legal text. Execution infrastructure does not yet support it. Track whether the drug-side barriers, discount flow recognition, hospital listing friction, and physician incentive adjustments resolve in the current formulary cycle before treating commercial insurance as an actionable device pathway.
For strategic teams monitoring pricing signals. The red-yellow label formalisation for competitive drugs is a forward signal for high-value consumable pricing governance. Provinces including Tianjin, Fujian, and Heilongjiang have applied analogous warning mechanisms to medical device procurement. Formalisation at the national formulary level is a precedent signal, not a confirmed extension, that similar logic may migrate to device-side price management.
— OphthalLogix Intelligence
This analysis is based on publicly available policy documents and independent analytical judgement. It does not constitute legal, regulatory, or investment advice. Policy details are subject to change following the public consultation process; verify against official documents before acting on this content. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.
intelligence@ophthallogix.com · www.ophthallogix.com